NRAS, KRAS, BRAF, TP53, FAM46C, DIS3, CCND1, and other genes, are thought to contribute to the pathogenesis of MM and are clinical biomarkers for the selection of targeted therapeutic strategies. This evidence concerns the gene CCND1 and Miyoshi myopathy.